BR112017016434A2 - ?cristal de um anticorpo monoclonal anti-pd-1, métodos para produzir cristais de um anticorpo monoclonal anti-pd-1, para cristalizar um anticorpo monoclonal anti-pd-1 e para tratamento de um indivíduo humano, e, composição farmacêutica? - Google Patents
?cristal de um anticorpo monoclonal anti-pd-1, métodos para produzir cristais de um anticorpo monoclonal anti-pd-1, para cristalizar um anticorpo monoclonal anti-pd-1 e para tratamento de um indivíduo humano, e, composição farmacêutica?Info
- Publication number
- BR112017016434A2 BR112017016434A2 BR112017016434A BR112017016434A BR112017016434A2 BR 112017016434 A2 BR112017016434 A2 BR 112017016434A2 BR 112017016434 A BR112017016434 A BR 112017016434A BR 112017016434 A BR112017016434 A BR 112017016434A BR 112017016434 A2 BR112017016434 A2 BR 112017016434A2
- Authority
- BR
- Brazil
- Prior art keywords
- monoclonal antibody
- crystals
- treatment
- methods
- crystallize
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
são providos cristais de pembrolizumab e anticorpos monoclonais anti-pd-1 estruturalmente similares, e também são providos métodos para produzir tais cristais, e usos de composições compreendendo tais cristais de anticorpo, por exemplo, no tratamento de cânceres. a presente invenção satisfaz a estas necessidades e, mais, pelo provimento de cristais de pembrolizumab e de um método para produzir cristais de pembrolizumab. uma modalidade do método da invenção produz cristais adequados para difração de raios-x, e os inventores da presente invenção usaram tais cristais para solucionar a estrutura tridimensional de pembrolizumab para resolução de 2,3 å.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562121867P | 2015-02-27 | 2015-02-27 | |
| PCT/US2016/018843 WO2016137850A1 (en) | 2015-02-27 | 2016-02-22 | Crystals of anti-human pd-1 monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017016434A2 true BR112017016434A2 (pt) | 2018-04-10 |
| BR112017016434A8 BR112017016434A8 (pt) | 2023-04-11 |
Family
ID=56789127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017016434A BR112017016434A8 (pt) | 2015-02-27 | 2016-02-22 | Cristal de um anticorpo monoclonal anti-pd-1, métodos para produzir cristais de um anticorpo monoclonal anti-pd-1 e para cristalizar um anticorpo monoclonal anti-pd-1, bem como e composição farmacêutica e seu uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11014986B2 (pt) |
| EP (1) | EP3261663A4 (pt) |
| JP (1) | JP6999419B2 (pt) |
| KR (1) | KR102622285B1 (pt) |
| CN (1) | CN107249624B (pt) |
| AR (1) | AR103726A1 (pt) |
| AU (2) | AU2016223047A1 (pt) |
| BR (1) | BR112017016434A8 (pt) |
| CA (1) | CA2975623A1 (pt) |
| MX (1) | MX2017011003A (pt) |
| RU (1) | RU2017133449A (pt) |
| TW (1) | TWI714552B (pt) |
| WO (1) | WO2016137850A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
| EA201890630A1 (ru) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | Антитела против pd-1 и способы их применения |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
| EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
| CN110300599A (zh) | 2016-12-07 | 2019-10-01 | 艾吉纳斯公司 | 抗体和其使用方法 |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2019072566A1 (en) | 2017-10-10 | 2019-04-18 | Biotest Ag | COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER |
| US20210047408A1 (en) * | 2018-02-13 | 2021-02-18 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti-pd-1 antibodies |
| MA54089A (fr) * | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| KR20230053614A (ko) | 2020-07-31 | 2023-04-21 | 메사추세츠 인스티튜트 오브 테크놀로지 | 고체 형태의 폴리펩티드를 포함하는 조성물 및 관련 방법 |
| CN112300284B (zh) * | 2020-12-29 | 2021-04-06 | 慈达(广州)生物技术有限公司 | 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US6402051B1 (en) | 2000-10-27 | 2002-06-11 | Deere & Company | Fold cylinder structure |
| EP1801123A3 (en) * | 2000-12-28 | 2007-11-21 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| KR20100031769A (ko) | 2000-12-28 | 2010-03-24 | 알투스 파마슈티컬스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| US6955717B2 (en) | 2001-05-01 | 2005-10-18 | Medimmune Inc. | Crystals and structure of Synagis Fab |
| JP2005500304A (ja) | 2001-06-21 | 2005-01-06 | アルタス バイオロジックス インコーポレイテッド | 球状タンパク質粒子およびそれらの作製方法および使用方法 |
| PT2206517T (pt) * | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
| ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
| DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| CN101218351A (zh) * | 2005-02-15 | 2008-07-09 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
| ES2427646T5 (es) * | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
| WO2006133486A1 (en) * | 2005-06-14 | 2006-12-21 | The Macfarlane Burnet Institute For Medical Research And Public Health Limited | CRYSTAL STRUCTURES AND MODELS FOR Fc RECEPTOR:Fc COMPLEXES AND USES THEREOF |
| CA2667655A1 (en) | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
| CN101605906A (zh) * | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| RU2476442C2 (ru) | 2007-03-29 | 2013-02-27 | Эббот Лэборетриз | Кристаллические антитела против il-12 человека |
| RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| PT2242773T (pt) * | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | ANTI-GITRANT ANTIBODIES |
| EP2478005B1 (en) * | 2009-09-15 | 2014-11-12 | Ajinomoto Althea, Inc. | Protein a crystals and cross-linked crystals and methods of use thereof |
| AU2012236962B2 (en) | 2011-03-25 | 2017-05-11 | Amgen Inc. | Anti-sclerostin antibody crystals and formulations thereof |
| LT2691112T (lt) * | 2011-03-31 | 2018-07-25 | Merck Sharp & Dohme Corp. | Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai |
| EP2866833B1 (en) | 2012-06-27 | 2019-05-15 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
| JP6503349B2 (ja) * | 2013-07-23 | 2019-04-17 | ノバリック ゲーエムベーハー | 安定化された抗体組成物 |
| TWI649308B (zh) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| WO2016024228A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
| SG11201708223QA (en) | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
-
2016
- 2016-02-18 AR ARP160100432A patent/AR103726A1/es unknown
- 2016-02-22 WO PCT/US2016/018843 patent/WO2016137850A1/en active Application Filing
- 2016-02-22 BR BR112017016434A patent/BR112017016434A8/pt active Search and Examination
- 2016-02-22 CN CN201680008370.7A patent/CN107249624B/zh active Active
- 2016-02-22 RU RU2017133449A patent/RU2017133449A/ru unknown
- 2016-02-22 CA CA2975623A patent/CA2975623A1/en active Pending
- 2016-02-22 KR KR1020177026777A patent/KR102622285B1/ko active IP Right Grant
- 2016-02-22 MX MX2017011003A patent/MX2017011003A/es unknown
- 2016-02-22 US US15/553,254 patent/US11014986B2/en active Active
- 2016-02-22 JP JP2017544924A patent/JP6999419B2/ja active Active
- 2016-02-22 AU AU2016223047A patent/AU2016223047A1/en not_active Abandoned
- 2016-02-22 EP EP16756100.0A patent/EP3261663A4/en active Pending
- 2016-02-23 TW TW105105288A patent/TWI714552B/zh active
-
2022
- 2022-01-11 AU AU2022200142A patent/AU2022200142A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11014986B2 (en) | 2021-05-25 |
| JP2018510142A (ja) | 2018-04-12 |
| RU2017133449A3 (pt) | 2019-08-28 |
| WO2016137850A1 (en) | 2016-09-01 |
| EP3261663A4 (en) | 2018-10-03 |
| CN107249624B (zh) | 2023-01-31 |
| KR102622285B1 (ko) | 2024-01-05 |
| CN107249624A (zh) | 2017-10-13 |
| AR103726A1 (es) | 2017-05-31 |
| TWI714552B (zh) | 2021-01-01 |
| AU2022200142A1 (en) | 2022-02-10 |
| RU2017133449A (ru) | 2019-03-27 |
| TW201639886A (zh) | 2016-11-16 |
| KR20170120155A (ko) | 2017-10-30 |
| MX2017011003A (es) | 2017-10-20 |
| BR112017016434A8 (pt) | 2023-04-11 |
| US20180237524A1 (en) | 2018-08-23 |
| JP6999419B2 (ja) | 2022-02-10 |
| EP3261663A1 (en) | 2018-01-03 |
| CA2975623A1 (en) | 2016-09-01 |
| AU2016223047A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017016434A2 (pt) | ?cristal de um anticorpo monoclonal anti-pd-1, métodos para produzir cristais de um anticorpo monoclonal anti-pd-1, para cristalizar um anticorpo monoclonal anti-pd-1 e para tratamento de um indivíduo humano, e, composição farmacêutica? | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| ECSP20018586A (es) | Compuestos que contienen pirazolopirimidinona y sus usos | |
| BR112019017329A2 (pt) | imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição | |
| CY1121832T1 (el) | Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15) | |
| BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
| BR112017016636A2 (pt) | formulação líquida estável para anticorpos monoclonais | |
| EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| EA201891489A1 (ru) | Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| CO2018003452A2 (es) | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso | |
| BR112016027912A2 (pt) | molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer | |
| CL2018000622A1 (es) | Acetamida tienodiazepinas de triazol y sus usos relacionados. | |
| MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
| BR112021019334A2 (pt) | Anticorpos de cadeia pesada que se ligam ao psma | |
| PH12019501319A1 (en) | Gremlin-1 crystal structure and inhibitory antibody | |
| EA202290054A1 (ru) | Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3 | |
| MX2021005085A (es) | Formulacion de anticuerpo. | |
| CO2018012497A2 (es) | Anticuerpos de interferón beta y usos de los mismos | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| WO2018087143A3 (en) | Anti-pd-1 antibodies | |
| GT201700126A (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |